Volume 6.17 | May 15

Prostate Cell News 6.17 May 15, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
 
TOP STORY
miR-145 Suppress the Androgen Receptor in Prostate Cancer Cells and Correlates to Prostate Cancer Prognosis
Researchers characterized the mechanisms by which miR-145 deregulation contributed to prostate cancer progression. miR-145 was found to regulate androgen dependent cell growth in vitro. [Carcinogenesis] Abstract
FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Oncogenic Activity of miRNA 650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression
High levels of miRNA 650 (miR-650) was found in prostate cancer samples and cell lines. Inhibition of miR-650 reversed the expression suppression of cellular stress response 1 (CSR1), suppressed colony formation, and blocked cell cycle entry to the S phase of both PC3 and DU145 cells. [Am J Pathol] Abstract

Niclosamide Suppresses Cell Migration and Invasion in Enzalutamide Resistant Prostate Cancer Cells via Stat3-AR Axis Inhibition
Sensitivity of prostate cancer cells to enzalutamide was tested using cell growth assays and clonogenic assays. Wound healing and invasion assays were performed to determine cell migration and invasion in vitro. [Prostate] Abstract

miR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer
Aldehyde dehydrogenase 1A3 (ALDH1A3) expression was significantly downregulated in PC3, LNCaP and DU-145 cells after miR-187 re-introduction. The expression of ALDH1A3 was found significantly up-regulated in prostate cancer samples and inversely correlated with miR-187 expression. [PLoS One] Full Article

Optimization of Invasion-Specific Effects of Betulin Derivatives on Prostate Cancer Cells through Lead Development
The effects of betulin derivatives on cell cycle progression, mitosis, proliferation and unspecific cytotoxicity, versus their ability to specifically interfere with cell motility and tumor cell invasion was addressed. [PLoS One] Full Article

Combination of Curcumin and Bicalutamide Enhanced the Growth Inhibition of Androgen-Independent Prostate Cancer Cells through SAPK/JNK and MEK/ERK1/2-Mediated Targeting NF-κB/p65 and MUC1-C
Investigators showed that curcumin inhibited the growth of androgen-independent prostate cancer cells and a synergy was observed in the presence of curcumin and bicalutamide, the androgen receptor antagonist. To further explore the potential mechanism underlining this, they found that curcumin increased the phosphorylation of ERK1/2 and SAPK/JNK, which was enhanced by bicalutamide. [J Exp Clin Cancer Res]
Abstract
| Full Article

miR-124 Suppresses Cell Motility and Adhesion by Targeting Talin 1 in Prostate Cancer Cells
MicroRNA (miR)-124 was down-regulated in prostate cancer specimens and cell lines, while talin 1 was over-expressed in prostate cancer specimens and cell lines. [Cancer Cell Int] Full Article

CLINICAL RESEARCH

Resveratrol Reduces the Levels of Circulating Androgen Precursors but Has No Effect on, Testosterone, Dihydrotestosterone, PSA Levels or Prostate Volume. A 4-Month Randomized Trial in Middle-Aged Men
In a randomized placebo controlled clinical study using two doses of resveratrol for four months, scientists evaluated the effects on prostate size, prostate specific antigen and sex steroid hormones in 66 middle-aged men suffering from the metabolic syndrome. [Prostate] Abstract

Pre-Existing Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab
A Phase Ib trial in patients with metastatic, castration resistant prostate cancer was performed combining ipilimumab with sargramostim. In addition to evaluating ipilimumab dose, patients were followed clinically for response and overall survival, and for immunomodulation of circulating T cells. [Cancer Immunol Res] Abstract

Cryopreservation Media for Stem Cells - Learn More!
 
REVIEWS
Targeted Therapies for Prostate Cancer
New therapies for prostate cancer have emerged over the past three years. Nevertheless, none of these agents is curative, and unfortunately, patients often ultimately develop resistance to these agents. Therefore, the development of innovative and effective therapies that overcome these resistances is necessary. [Cancer Invest] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Target Cancer Metabolism
 
SCIENCE NEWS
New Cancer Treatment and Prevention Studies Signal Major Advances for Children and Adults
The American Society of Clinical Oncology (ASCO) announced results from four major studies. One study showed that early chemotherapy extends the lives of men with advanced prostate cancers. [Press release from ASCO discussing research to be presented at the 2015 ASCO Annual Meeting, Chicago] Press Release

From our sponsor:
Optimize your ALDHbr cell detection with tissue-specific ALDEFLUOR™ protocols.
Watch the video.
 
INDUSTRY NEWS
Propanc to Study Effects of PRP on Cancer Stem Cells
Propanc Health Group Corporation announced that the Company will be investigating the effects of PRP against cancer stems cells with its joint research partner at the University of Jaén, Spain. [Propanc Health Group Corporation] Press Release

Redx Reaches Pre-Clinical Proof of Concept with Oncology Lead
Redx Pharma has reached pre-clinical proof of concept stage with an advanced lead which has the potential to tackle some of the most hard-to-treat cancers. The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signaling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types. [Redx Pharma Plc] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 18th International Conference on Cell and Stem Cell Engineering (ICCSE)
September 15-16, 2016
Rome, Italy

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW PhD Student – Design and Evaluation of an Antibody-Drug Conjugate for Prostate Cancer Treatment (Swansea University)

NEW PhD Student – Cancer Stem Cell Immunology (Cardiff University)

Postdoctoral Positions – Molecular Cancer Biology (University of Pennsylvania)

Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

Postdoctoral Research Fellow/Instructor – Prostate/Breast Cancer (Baylor College of Medicine)

Scientific Officer – Prostate Oncobiology Group (Cancer Research UK Manchester Institute)

Postdoctoral Fellow – Genitourinary Cancers (Geisinger Health System)

Cancer Biologist (Wake Forest Baptist Medical Center)

Postdoctoral Fellow – Development, Progression and Chemotherapy Resistance of Cancers (University of Maryland School of Medicine)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us